NYSE: SOLV · Medical Instruments & Supplies

Solventum (SOLV) fair value: undervalued or overvalued?

As of 14 Nov 2026, Faircurve's model values Solventum (SOLV) at $88.47 a share. The stock last closed at $88.65, which puts the model's fair value 0.2% below the price. On the model's bands that reads as Fairly valued.

Revalued . Price is the close of 16 Nov 2026. Solventum Corporation.

The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.

Model fair value$88.47midpoint of 2,000 simulations
Last close$88.65NYSE: SOLV
Gap to fair value-0.2%fair value against price
Model verdictFairly valuedevidence grade: High

This week, in three parts

What happenedThe run of 14 Nov 2026 held the fair value at $88.47, within 1% of the run of 7 Nov 2026.

What the model makes of itThe price of $88.65 is level with it: Fairly valued, on a high evidence grade.

What's nextNext report on 25 Feb 2027. The next weekly run is on Saturday 21 Nov 2026.

What price range does the model give SOLV?

The calibrated range for SOLV over 63 trading days is $70.75 to $105.10. There is no live options data for this stock, so the range is built from the fair value and calibrated weekly against realised prices (n = 13,250 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon.

The model's own simulated range, from the 20th to the 80th percentile of its runs, is $69.80 to $109.58. In 49% of the simulations the fair value came out above the price the model ran on.

$51.34$143.78
Spread of the 2,000 simulated fair values. Solid line: the midpoint, $88.47. Dashed line: the last close, $88.65.

Faircurve Insights · 14 Nov 2026

Solventum Corporation is headquartered in Saint Paul, Minnesota. Established in 2023, it operates as a healthcare entity dedicated to pioneering, producing, and commercializing diverse solutions that address critical needs for both customers and patients.

Faircurve's model put the fair value of Solventum at $88.47 a share on 14 Nov 2026, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $88.78, so the fair value moved -0.3%. The calibrated range over 63 trading days is $70.75 to $105.10, built from the fair value because there is no live options data for the stock. Ranges built this way held the price 60% of the time at this horizon. The evidence grade is High, based on input completeness, the number and agreement of comparable companies, and the width of outcomes. It does not say whether the fair value is right.

The model's overall quality score is 45 out of 100, scored against comparable companies. Profitability scores 100, with ROIC of 19.1% against a peer median of 4.2%. Earnings quality scores 0, with FCF / net income of 0.01x against a peer median of 1.55x. The model compares Solventum with Baxter International, The Cooper Companies, Repligen, Avantor, AptarGroup, West Pharmaceutical Services, ResMed and Teleflex.

Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.

The Global Pulse

Faircurve's note after each US session, in your inbox. No account needed.

When does SOLV report earnings, and how has the stock reacted?

Solventum's next earnings report is scheduled for 25 Feb 2027. Companies can move their dates.

Around its last 8 reports: what the options market priced, and what followed

Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across SOLV's last 8 reports, ignoring direction, was 5.2%.

0%5%10%15%9.8%5.1%27 Feb '2511.4%7.2%8 May '258.1%1.1%7 Aug '25no quote5.7%6 Nov '25no quote1.2%26 Feb '2613.2%5.3%5 May '2611.7%5.7%5 Aug '2611.0%1.2%5 Nov '26priced before the reportthe move that followed
What the options market priced for each report, against the size of the move that followed. Priced: the move implied by options expiring after the report, on the last quote before it. Followed: the close before the report to the close after. Sizes only, no direction.

What the options market has priced for a month's move in SOLV

5%10%15%20%5 Nov '26 report5 Aug '26 report5 May '26 report26 Feb '26 report10% at 6 Nov '2626 Feb '266 Nov '26
What the options market priced for a month's move (30-day implied volatility, scaled to one month). It read 13% on 26 Feb 2026, reached 15% on 23 Oct 2026 and reads 10% on 6 Nov 2026. The marks are report dates.

How does SOLV score on business quality?

Solventum's overall quality score is 45 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.

FactorScore (0 to 100)Headline measurePeer median
ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend.10019.1%ROIC4.2%
Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash).00.01xFCF / net income1.55x
Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes.330.9%Revenue growth, trailing5.1%
Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks.562.7%Net buybacks / market value2.4%
Balance sheetNet debt to EBITDA and interest coverage.166.02xNet debt / EBITDA2.54x
StabilityDownside volatility of the EBITDA margin over the last five years.113.8 ptsEBITDA margin downside volatility, 5y1.4 pts

How does SOLV compare with similar companies?

The companies in medical instruments & supplies closest to Solventum in market value, each on the same model and the same date.

CompanyLast closeModel fair valueGapModel verdict
BAX Baxter International Inc.$25.54$24.84-2.7%Fairly valued
COO The Cooper Companies, Inc.$61.88$70.88+14.5%Fairly valued
RGEN Repligen Corporation$162.78$152.66-6.2%Fairly valued
AVTR Avantor, Inc.$15.32$20.70+35.1%Undervalued
ATR AptarGroup, Inc.$143.17$137.10-4.2%Fairly valued
WST West Pharmaceutical Services, Inc.$417.80$372.00-11.0%Fairly valued
RMD ResMed Inc.$238.19$271.74+14.1%Fairly valued
TFX Teleflex Incorporated$157.10$169.00+7.6%Fairly valued

What the comparable companies' multiples alone would give for SOLV, the peer-implied price, is $87.18 a share on this run. The fair value weighs that against the company's own multiple.

All medical instruments & supplies stocks ranked by gap to fair value

Solventum at a glance

Solventum Corporation, established in 2023 and headquartered in Saint Paul, Minnesota, operates as a healthcare entity dedicated to pioneering, producing, and commercializing diverse solutions that address critical needs for both customers and patients.

Market value
$15.1B
Sector
Healthcare
Industry
Medical Instruments & Supplies
Revenue expected, next twelve months
$8.5B
Consensus revenue growth, next fiscal year
-0.9%
Analysts with estimates
9
Beta to the US market
0.48
First valued by Faircurve
1 May 2026

At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. SOLV was not among them.

How the fair value is worked out: the model prices Solventum on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.

What changed in the latest valuation?

On 7 Nov 2026 the model's fair value for SOLV was $88.78. As of 14 Nov 2026 it is $88.47, a change of -0.3%. The model revalues every stock it covers each week, and again after an earnings report.

Questions about Solventum's valuation

Is Solventum stock undervalued or overvalued?

On Faircurve's model, SOLV reads as Fairly valued as of 14 Nov 2026. The model's fair value is $88.47 a share against a last close of $88.65, a gap of -0.2%.

What is SOLV's fair value?

$88.47 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $69.80 to $109.58.

What price range does the model give SOLV?

$70.75 to $105.10 over 63 trading days. Ranges built this way held the price 60% of the time across 13,250 past valuations, refreshed 14 Nov 2026.

When does Solventum report earnings next?

The next report is scheduled for 25 Feb 2027. Companies can move their dates.

How much has SOLV moved on past earnings reports?

Across its last 8 reports the median two session move was 5.2%, ignoring direction. The largest was +7.2% around the report of 8 May 2025.

How confident is the model in this valuation?

The model's evidence grade for SOLV is high. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.

The model's own ideas on SOLV

The model holds no idea open on SOLV today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on SOLV with their outcomes. A free account is enough.

Keep reading